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Although neurofibrillary tangle (NFT) formation is a central event in both familial and sporadic Alzheimer's disease (AD), neither cellular
origin nor functional consequence of the NFTs are fully understood. This largely is due to the lack of available in vivo models for neurofibrillary
degeneration (NFD). NFTs have only been identified in transgenic mice, bearing a transgene for a rare hereditary neurodegenerative disease,
frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP17). Epidemiological evidence suggests a much higher occurrence of
dementia in stroke patients. This may represent the underlying cause of the pathogenesis of sporadic AD, which accounts for the majority of AD
cases. We examined pathological markers of AD in a rodent stroke model. Here we show that after transient cerebral ischemia,
hyperphosphorylated tau accumulates in neurons of the cerebral cortex in the ischemic area, forms filaments similar to those present in human
neurodegenerative tauopathies and colocalizes with markers of apoptosis. As a potential underlying mechanism, we were able to determine that
transient ischemia induced tau hyperphosphorylation and NFT-like conformations are associated with aberrant activation of cyclin dependent
kinase 5 (Cdk5) and can be rescued by delivery of a potent, but non-specific cylclin dependent kinase inhibitor, roscovitine to the brain. Our study
further indicates that accumulation of p35 and its calpain-mediated cleavage product, p25 may account for the deregulation of Cdk5 induced by
transient ischemia. We conclude that Cdk5 may be the principal protein kinase responsible for tau hyperphosphorylation and may be a hallmark of
the tauopathies in this stroke model.
© 2006 Elsevier B.V. All rights reserved.Keywords: Tauopathy; Tau; Hyperphosphorylated tau; Neurofibrillary tangle; CDK5; Roscovitine1. Introduction
Dysfunctional and filamentous microtubule-binding tau
proteins are key markers of both sporadic and familial
neurodegenerative pathologies. A large number of neurodegen-
erative diseases, including AD, Pick's disease, progressive
supranuclear palsy, corticobasal degeneration, and FTDP-17,
showed progressive accumulation of dysfunctional tau inclu-
sions [1]. Collectively, these diseases are known as neurode-
generative tauopathies. In AD, NFTs and neuropil thread⁎ Corresponding author. Department of Pharmacology and Neuroscience,
University of North Texas Health Science Center at Fort Worth, 3500 Camp
Bowie Blvd., Fort Worth, TX 76107 2699, USA, Tel.: +1 817 735 0498.
E-mail address: JSIMPKIN@hsc.unt.edu (J.W. Simpkins).
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doi:10.1016/j.bbadis.2006.10.011pathologies are found intracellularly in conjunction with the
deposition of β-amyloid (Aβ) fibrils in the extracellular space.
The dominant components of neurofibrillary lesions in AD are
hyperphosphorylated tau that forms paired helical filaments
(PHFs) and straight filaments [2–4].
Tau proteins are microtubule-associated proteins that are
expressed abundantly in axons. Both in vivo and in vitro studies
indicate that tau proteins bind to microtubules, promoting their
polymerization [5,6]. Multiple isoforms are expressed in the
CNS by alternative mRNA splicing [7,8] and the tau isoforms
observed in PHFs of AD are similar to those observed in normal
adult human brain [9,10]. There are 79 potential serine and
threonine phosphorylation sites on the longest human tau
isoform. Phosphorylation of more than 30 of these moieties
have been reported [11,12]. These phosphorylation sites are
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higher in embryonic than adult CNS [13]. These phosphoryla-
tion sites cluster in the flanking region that negatively regulates
tau's binding affinity to microtubules [14–16]. However, the
relative importance of individual phosphorylation sites is still
controversial.
A large number of Ser/Thr kinases are able to phosphorylate
tau, including mitogen-activated protein kinase (MAPK)
[16,17], glycogen synthase kinase 3β (GSK-3β) [18], cyclin
dependent kinase 2 (cdk2) [19], cdk5 [20], cAMP dependent
kinase [21], and Ca/calmodulin-dependent kinase II [22].
However, most of these protein kinases that potentially mediate
tau phosphorylation were identified in in vitro studies, and the
specific kinases that regulate tau phosphorylation under
physiological or pathological conditions remain to be deter-
mined. Recent data indicate that both cdk5 and GSK3-βmay be
involved in the in vivo regulation of tauopathies [19,23–26].
The prevalence of dementia in ischemic stroke patients is
nine times higher than controls at 3 months [27] and 4–12 times
higher than controls at 4 years after a lacunar infarct [28]. Many
of these dementias develop progressively and cerebral damage
is not the direct cause of the subsequent dementia in most of the
cases [29]. AD is the most prevalent dementia [30] and shares
common neuropathology features with stroke. Alz-50-immu-
noreactive granules are found around cerebral infarction after a
stroke [31], amyloid precursor protein (APP) accumulates
following transient focal ischemia [32], and ApoE4 is a genetic
risk factor for both AD and stroke [33].
Cdk5, also known as neuronal cdc2-like kinase, is widely
expressed in many tissues [34], but its highest expression and
associated kinase activity are detected only in the nervous
systems [35,36]. Cdk5 shows no enzymatic activity until it
associates with its co-activator, p35 or p39. One of the best-
studied co-activator is p35, which can be enzymatically cleaved
to p25 [37,38]. P25 contains all the elements necessary for cdk5
binding and activation. However, p25 has a substantially longer
half-life than p35 and lacks the amino-terminal myristoylation
site, causing it to concentrate in the cell body and nucleus, while
p35 is more concentrated near the tips of neuronal processes
[34]. Aberrant induction of p25 can cause extended Cdk5
activation and can redirect Cdk5 to alternative substrates to
initiate apoptosis and neurodegeneration [34].
In the present study, we assessed tau-hyperphosphorylation
and Alzheimer-like tangle formation in a rodent model for
transient cerebral ischemia. We also examined the protein
kinases that are potentially involved in the stroke-induced
tauopathy.
2. Materials and methods
2.1. Animals and ovariectomy
Female Sprague–Dawley were purchased from Charles River Labs
(Wilmington, MA) and maintained in pairs in temperature-controlled rooms
(22–25 °C) with 12-h light–dark cycles. All rats had free access to laboratory
chow and tap water. All animal procedures were reviewed and approved by the
University of North Texas Health Science Center Institutional Animal Care and
Use Committee, and adhered to followed current standards.2.2. Animal surgeries
In order to avoid fluctuations of estrogens, which is neuroprotective [39,40],
all animals received bilateral ovariectomy. Animals were anesthetized with
ketamine (60 mg/kg) and xylazine (10 mg/kg). A small cut was made through
skin and muscle, and ovaries were externalized and removed. Ovariectomies
were performed at least 2 weeks before any further procedure.
For middle cerebral artery (MCA) occlusion and reperfusion, an intraluminal
filament model was used [39,41]. To achieve a transient MCA occlusion, the
internal carotid artery (ICA) was exposed, and a 3-0 monofilament nylon suture
was introduced into the ICA lumen through a puncture and was gently advanced
about 2 cm to the distal internal carotid artery (ICA) until proper resistance was
felt. After 1 h, the suture was withdrawn from the ICA and the ICA was
immediately cauterized. Each treatment group included 3–4 animals.
The brain was then dissected either coronally into 2-mm sections using a
metallic brain matrix (ASI Instruments, Inc., Warren, MI), and stained by
incubation in a 2% 2,3,5-Triphenyl-2H-tetrazolium chloride (TTC) in a 0.9%
saline solution at 37 °C for 30 min. Then the slices were fixed in 4%
paraformaldehyde, processed for paraffin embedding and sectioned to 5 μm for
immunohistochemical analysis.
2.3. Roscovitine delivery
Rats were anesthetized and placed in a stereotaxic device. Surgical stainless
steel microsyringe were temporarily inserted into the brain, so that the tip of the
syringe needle would be inserted into the lateral ventricle: antero-posterior, −5;
lateral, 1.8 from bregma; and −7.9 ventral from the dura. The insertion was
confirmed with post-mortem dissection. Animals were administered 50 μl of 1 mM
roscovitine (Sigma-Aldrich, St. Louis, WA), a potent, but non-specific cyclin
dependent kinase inhibitor, in 30% 2-hydroxypropyl-β-cyclodextrin (HPβCD) into
the right lateral ventricle over a period of 5 min using a microinjection syringe
(equivalent to approximately 20 μM final roscovitine in the brain). The needle was
held in position for at least another 30 min to avoid leaking. Sham treated animals
received an equal volume of 30% HPβCD. Roscovitine was delivered at least 2 h
before MCA surgery.
2.4. Immunoblotting
For immunoblotting analysis with various antibodies, frontoparietal cortex
was dissected from brain tissues and homogenized in RIPA buffer (1× PBS, 1%
Nonidet P-40 or Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM
sodium orthovanadate, 10 μg/ml Aprotinin, 100 μg/ml Phenylmethyl Sulphonyl
Fluoride (PMSF)). Samples were incubated on ice for 20 min and then
centrifuged at 12,000×g for 20 min. Supernatants were collected for further
analysis. Samples were separated on 10% or 8–16% gradient SDS-
polyacrylamide gels and electrophoretically transferred to a nitrocellulose
membrane. Membranes were blocked by incubation with blocking buffer (5%
dry milk in phosphate-buffered saline (PBS) and 0.02% Tween 20 (PBST)) for
1 h at room temperature, followed by over-night incubation at 4 °C with the
appropriate primary antibody in blocking buffer. After thorough washing, the
membrane was incubated with species-specific HRP-conjugated secondary
antibodies for 1 h at room temperature, followed by another thorough wash in
PBST. The membrane was then incubated and the blots were developed with an
enhanced chemiluminescent kit (Pierce, Rockford, IL).
2.5. Immunohistochemistry and TUNEL Staining
For immunohistochemical analysis, animals were perfused transcardially with
4% paraformaldehyde in sodium phosphate buffer (pH 7.4). Brains were
harvested, paraffin-embedded, and sectioned into 5 to 7 μm slices. Immunohis-
tochemical analysis was performed using an HRP-DAB kit, following the
manufacturer's recommended procedure (Zymed, South San Francisco, CA).
Some of the sections were pretreated with 100 μg/ml proteinase K in PBS for
15 min for antigen retrieval, and signal enhancement. After staining, sections
were dehydrated in a gradient of ethanol and xylene, and then were sealed with
cover slips. All photographs were taken using a Nikon Diaphot 300 microscope and
a 12-bit CCDmonochrome camera,with labworks software (UVP Inc,Upland, CA).
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Labeling (TUNEL) method with The DeadEnd™ Fluorometric TUNEL System
(Promega, Madison, WI) according to manufacturer's instruction. Sections were
counter-stained with 4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI)
(Molecular Probes, Eugene, OR). Colocalization of TUNEL with specific anti-
gens was achieved by performing TUNEL in the presence of antibody, followed
by the detection with highly specific Alexa-Fluorochrome conjugated secondary
antibodies (Molecular Probes, Inc. Eugene, OR), whose excitation/emission
spectra do not overlap with that of the FITC label, used in the TUNEL stain.
Antibodies used in the immunohistochemical assays include antibodies
directed against Cdk5 (H291) and P35/P25 (C-19) at a dilution of 1:50 (Santa
Cruz Biotech. Santa Cruz, CA). The following antibodies were used to label the
conformation and phosphorylation dependent tau epitopes in the brain sections:
MC1 (conformation dependent), TG3 (Phospho-tau 231 and AD conformation),
CP13 (Phospho-tau 202/205), CP3 (Phospho-tau 214), PHF-1 (Phospho-tau
396/404), and CP9 (Phospho-tau 231) at a dilution of 1:10. All of the above-
mentioned NFT specific-antibodies were characterized by and were the kind
gifts of Dr. Peter Davies (Albert Einstein College of Medicine).
2.6. Sarcosyl tau extraction
Sarcosyl extractions were performed as described previously [42]. In brief,
brain tissues from ischemic and contralateral rat cortex were homogenized in
10 volumes of buffer consisting of 10 mM Tris–HCl (pH 7.4), 0.8 M NaCl,
1 mM EGTA, and 10% sucrose. The homogenate was centrifuged for 20 min at
20,000×g. The supernatant was brought to 1% N-lauroylsarcosinate (Sarcosyl)
and incubated for 1 h at room temperature with moderate shaking. Samples were
then centrifuged at 100,000×g for 1 h at 4 °C, the sarcosyl-insoluble pellets were
resuspended in 50 mM Tris–HCl (pH 7.4) and temporally stored at 4 °C, or at
−80 °C for long term storage until use. This material was used for both
immunoblotting analysis and electron microscopy analysis.
2.7. Electron microscopy
Resuspended sarcosyl-insoluble materials obtained from ischemic cortical or
contralateral extracts were placed directly on carbon-coated, 300-mesh grids,
stained with 2% phosphotungstic acid, and analyzed by electron microscopy
[43]. As negative controls, filament preparations from contralateral extracts wereFig. 1. Induction of apoptosis by transient cerebral ischemia in OVX rats. Depicted
occlusion and 24-h reperfusion with nuclear counter-stain (blue). (A) Contralateral co
was separated from fully perfused regions by the lateral ventricle; (D) ischemic subco
of panels A–E. Photographs A–E were taken from the same brain section near theexamined at the same time. Microphotographs were recorded at an operating
voltage of 80–100 kV and at nominal magnifications of 16,000 or 40,000, on a
Zeiss electron microscope (Leo EM 910).
2.8. Immunocomplex protein kinase assay
For immunoprecipitation, 250 μg of brain extracts were incubated with 1 μg
primary antibody at 4 °C with gentle shaking for 1 h Agarose conjugated Protein
A (20 μl) was added to the tube and incubated for 1 h at 4 °C with moderate
shaking. Immunoprecipitates were collected by centrifugation at 1000×g for
5 min at 4 °C. Pellets were washed three times with 1.0 ml lysis buffer and were
resuspended with in 20 μl of the protein kinase assay buffer (e.g., 50 mM
HEPES, 0.1 mM EDTA, 0.1 mg/ml BSA, 0.1% β-mercaptoethanol, 0.15 M
NaCl). Histone H1 (5 μg, Upstate Waltham, MA) was added to the protein
kinase assay buffer that contained a final concentration of 50 μM ATP with
1 μCi γ-32PATP (ICN Biomedicals, Inc. Irvine CA). After 15 min of reaction at
30 °C, the reaction was terminated by adding an equal volume of 2×
electrophoresis sample buffer and separated on SDS-PAGE for subsequent
autoradiography.
2.9. Affinity co-precipitation assay
Brain cortical extracts were incubated with recombinant tau, N-terminal 6X
histidine-tagged, (Sigma, St. Louis, WA) for 1 h at 4 °C with gentle shaking, and
purified with His-trap gel according to manufacturer's instruction (Amersham,
Piscataway, NJ). The purified product was separated with SDS-PAGE and
analyzed by immunoblotting with appropriate antibody.
2.10. Semi-quantitative cell counting
Brain sections from the rats that received roscovitine (n=6) or sham
treatment (n=3) were randomly selected to estimate the density of cortical cells
labeled with specific antigen, using the methods adapted from the previous
studies [44]. Each brain section was labeled with specific antigen or double
labeled with TUNEL immunohistochemistry. Cell counting was performed
under a CAST-Grid system (Nikon, Inc) in the region selected from the ischemic
brain cortex near the edge of superior surface, where the highest densities of
positive cells were observed in previous studies. The striatum were not includedare TUNEL (green) stained sections from various brain regions after 1-h MCA
rtex; (B) ischemic cortex; (C) periventricular region, where the ischemic region
rtex; (E) contralateral subcortex; (F) TTC stained brain slice to show the location
frontoparietal cortex in representative experiments. Scale bar=100 μm.
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boundaries, optical dissectors were systematically randomly sampled, and the
number of positive cells, together with DAPI labeled nuclear counter-stain in
each optical dissector was counted. The cell density in the investigated region
was calculated by dividing the number of positive cells counted by the total cell
numbers (labeled with DAPI). The data are expressed as the percentage of DAPI
counter-stained cells.
2.11. Densitometric analysis and statistical analysis
The images of autoradiography of immunoblotting were digitized and
imported using a calibrated scanner, at 16-bit gray mode to provide 65,536 gray
levels. The area density was quantified using Labworks software (UVP Inc,
Upland, CA). The unit given is an arbitrary unit that represents the total units per
band in the analyzed samples. The results were assayed with one-way ANOVA
statistical method with Prism software (Version 3.0).Fig. 2. Transient ischemia induces tau hyper-phosphorylation. (A–F) Representative
PHF-1 (detecting P-396/404) in the contralateral (A), ipsilateral (B), and ipsilateral in
(E), and CP9 (detecting P-231) (F) in frontoparietal cortex. Scale bar=100 μm. (G) t
contralateral (C) cortical region with specified antibody. (H) Illustration of the approx
and sagittal (right) section. The shaded area indicates the ischemic region; do
immunoreactivity is localized to the frontoparietal cerebral neocortex, with only a few
non-ischemic brain regions, such as hippocampus.3. Results
3.1. Induction of neuronal apoptosis by transient cerebral
ischemia
MCAocclusion in rodent is a widely used focal ischemic stroke
model, at which a synchronized apoptotic process can be rapidly
induced in a large number of neurons [41,45]. We examined the
effects of transient MCA occlusion on neuronal apoptosis, using a
TUNEL assay. As early as 2 h after the initiation of reperfusion,
positive TUNEL stainings appeared in the core ischemic region
near the basal ganglion areas (data not shown). At 24 h after
reperfusion, TUNEL positive cells were widespread in the
ischemic region, which includes fronto-parietal cerebral cortexcoronal sections of frontoparietal cerebral cortex showing immunoreactivity of
high magnification (C), CP3 (detecting P-214) (D), CP13 (detecting P-202/205),
he immunoblotting of sarcosyl extracted preparations from the ischemic (I), and
imate distribution of tau-hyperphosphorylation positive neurons in coronal (left)
tted area indicates approximate positive cell density. Most of the positive
immunoreactive cells present in subcortical areas. No staining was observed in
Fig. 3. Transient cerebral ischemia induces PHF-like conformation of tau protein. Tau phosphorylation and conformational changes occur 24 h after reperfusion in rats
that had undergone MCA occlusion. (A–C) Antibody TG3, a phosphorylation and conformation-dependent antibody, stains a subset of pyramidal neurons of the
cerebral cortical region in the ischemic region in low (B) and high (C) magnification, but not the contralateral cortex (A). (D–F) Antibody MC1, a conformation-
dependent antibody, the cerebral cortical region in the ischemic region in low (E) and high (F) magnification, but not the contralateral cortex (D). (G) Electron
microscopy analysis of the sarcosyl-extracted tau shows straight filaments that are approximately 20 nm wide, and resemble paired helical filaments observed in AD
patients. These filaments were not observed in the contralateral extracts.
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corresponding contralateral regions (Fig. 1A, E). In the penumbra
areas, where the lateral ventricle separates the ischemic from the
fully perfused area, TUNEL signals were observed only on the
ischemic side (Fig. 1C). In the subcortex, more than 80% of the
total cell population showed positive TUNEL signals in a variety
of cell types, which included neurons, astrocytes, glia, and some
epithelial cells of blood vessels, as determined by morphological
assessment. However in the neocortical area, most TUNEL-
positive cells represent the morphology of cortical pyramidalFig. 4. Colocalization of tau hyperphosphorylation with TUNEL, a marker of late a
colocalized with TUNEL positive cells (green) as shown in the merged image. Scalneurons as verified by microscopic examination. The distribution
of TUNEL signals was consistent with the result of TTC staining
for brain slices (Fig. 1F).
3.2. Aberrant hyperphosphorylation and conformational
alterations of tau in the ischemic cortical region
To characterize aberrant hyperphosphorylation of tau, we
used a panel of phospho-specific antibodies. While the
contralateral cortex was absent of phospho-specific immunor-poptotic events. In the ischemic cortical regions, PHF-1 positive staining (red)
e bar=100 μm.
Fig. 5. Tau affinity binding assay and cdk5 activity assay. (A) Affinity binding assay of potential tau protein kinases. The contralateral and ischemic homogenate
(input) was co-purified with His-tagged recombinant tau. The partially purified product (pull down) was examined using immunoblotting with the indicated antibodies.
(B) Immunoprecipitation-based cdk5 kinase assay with histone H1 as substrates. Each lane represents an individual animal.
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phospho-specific immunoreactivity in the ipsilateral regions,
specifically for PHF-1 (Fig. 2B, C), CP3 (Fig. 2D), CP13 (Fig.
2E), and CP9 (Fig. 2F). These antibodies showed a staining
pattern depicted in Fig. 2H. Briefly, most immunoreactivity was
observed in the peri-infarct area of the fronto-parietal cortex.
Many of positive cells can be clearly identified as pyramidal
cortical neurons by morphological assessment. The subcortex
lacked staining of neurons. PHF-1 and CP13 had the strongest
staining for the entire soma of any given neuron, while other
neurons showed only weak staining. Immunoblotting with the
phospho-specific antibodies (PHF-1, CP13, and TG3) on
sarcosyl-extracted cortical sample confirms the presence of
hyperphosphorylation of tau protein in the sarcosyl-insoluble
preparation. All three antibodies detected a band of about 69 kDa
molecular weight in the sarcosyl-insoluble extracts from the
ischemic cortex, but not the contralateral cortex (Fig. 2G).
To further characterize the phosphorylation and conforma-
tional status of tau in the ischemic regions, we also used two
conformation-dependent anti-tau antibodies. Antibody TG3
detects both phosphorylation and the unique conformation of
PHF-tau [43], while MC1 is a conformation-dependent anti-
body, which detects the Alz50 epitope of AD tau [46]. In the
ischemic region, a large number of pyramidal neurons were
immunopositive for TG3 (Fig. 3B, C) and MC1 (Fig. 3 E, F) in
the frontoparietal cortex, but not in the contralateral regions
(Fig. 3A, D). The staining pattern observed in TG3 and MC1
was similar to that observed with phospho-specific monoclonal
antibodies (Fig. 2).
One of the major hallmarks of tauopathy is the formation of
PHF-like filaments or straight filaments. To further character-
ize abnormal tau proteins in the ischemic region, we
investigated the filamentous conformation of tau protein,
using sarcosyl-insoluble preparations. In the ischemic extracts,
we observed many filamentous aggregates with irregular
appearance, while the contralateral extracts showed no such
aggregates (Fig. 3G). A very small fraction of these filaments
were similar to the paired helical filaments observed in ADbrains (Fig. 3G). The filamentous conformation is consistent
with that described in AD patient brains [1] and P301L
transgenic mice [43]. However, filaments had a much lower
density than in AD brains or the P301L animal model.
We further characterized the spatial relationship between
hyperphosphorylated tau and apoptotic markers, using a
double-staining method. In cortex, hyperphosphorylated tau
(PHF1, red) colocalized with TUNEL (green) in a large
proportion of TUNEL positive cells (Fig. 4) indicating that
tau hyperphosphorylation and apoptosis are correlated
events.
3.3. Activation-dependent interaction of cdk5 with tau
In order to characterize potential protein kinases responsible
for the transient ischemia induced tau hyperphosphorylation,
we used affinity assays with recombinant His-tagged tau as a
bait protein. We examined three proline directed protein
kinases, Cdk5, GSK3-β and ERK1, which had been reported
to phosphorylate tau in vitro and in vivo. GSK3-β, and ERK-1
showed only weak association with recombinant tau in the
affinity binding assays (Fig. 5A). However, Cdk5 showed
strong association with recombinant tau in the ischemic, but
not in the contralateral brain extracts (Fig. 5A). This was
consistent with our previous observation that hyperphosphor-
ylation of tau occurred only in the ischemic side. We
hypothesize that the differential affinity to tau protein is
related with the differential activation of Cdk5 in the ischemic
and contralateral cortical regions. We used an immunocomplex
protein kinase assay to evaluate Cdk5 activity. There was an
induction of Cdk5 activity in the ischemic brain extracts
compared with the contralateral extracts (Fig. 5B).
3.4. Deregulation of Cdk5 by its co-activator P35/P25 during
transient cerebral ischemia
Cdk5 is not activated by cyclins, but by its neuronal specific
co-activators, p35 or p39, as well as their cleaved product p25/
Fig. 6. Cdk5 co-activator p35/p25 in ischemic brain cortical extracts. (A)
Immunoblotting analysis of p35 and p25 of contralateral (lanes 1–4) or ischemic
(lanes 5–8) brain extracts. (B) Densitometric analysis of p35 cleavage in
contralateral and ischemic brain extracts. (C) Immunoblotting analysis of 100 μg
ipsilateral brain extracts for p35 and p25, with different time interval of
reperfusion indicated by the numbers above the blot. The onset of occlusion
occurred at −1 and reperfusion started at 0 h. (D) The densitometric analysis of
p35 cleavage in ischemic brain cortical extracts. * indicates a statistically
significant difference (P<0.05) between ischemic and contralateral extracts
determined by Student's t-test.
Fig. 7. Calpain activation is involved in p35 cleavage and Cdk5 activation
induced by transient ischemia. (A) Immunoblotting analysis of p35 cleavage
with recombinant rat calpain II. The first lane was loaded with 25 μg ischemic
brain extracts; other lanes are 100 μg contralateral brain extracts incubated with
the indicated amount of recombinant calpain II for 60 min at 37 °C. (B)
Immunoblotting analysis of p35/p25 in the cortical brain extract incubated with
5 mM calcium in the presence (lanes 5–8) or absence (lanes 1–4) of a calpain
inhibitor (MDL 28170) for 4 h at 37 °C.
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doubling in p35/p25 protein levels, and an 8-fold increase in the
p25 protein levels (Fig. 6A), which is a more potent coactivator
of Cdk5 and highly neurotoxic. We further analyzed the
temporal pattern of p35/p25 cleavage induced by this transient
cerebral ischemia in vivo. We found a time-dependent
accumulation of p35 that lasted at least 24 h after reperfusion
and a transient p25 production that started as early as 2 h and
peaked at 4 h after reperfusion (Fig. 6B).
Previously published research indicated that neurotoxicity-
induced calcium influx can activate calpain, a calcium
dependent protease, which cleaves p35 to p25 [37]. We
examined the p35 cleavage by incubating the brain cortical
extract with recombinant rat calpain II. Calpain II caused a
dose-dependent p35 cleavage into p25 (Fig. 7A). High
concentrations of calcium caused a similar cleavage activityin brain extracts, and the calpain inhibitor, MDL 28170,
attenuated this cleavage (Fig. 7B).
3.5. Inhibition of brain Cdk5 activity attenuates
tau-hyperphosphorylation and NFT-like conformational epitope
In order to further confirm the relationship between this tau
hyperphosphorylation and aberrant Cdk5 activation, we deliv-
ered roscovitine, a potent but non-specific cyclin-dependent
kinase inhibitor (Ki =0.7 μM), in the lateral ventricle. The effect
of this treatment was evaluated by both examining the phospho-
epitopes with TG3 labeling (Fig. 8A), by immunoblotting
analysis of the brain cortical extract, and by semi-quantitative
cell counting in the ischemic cortex. Roscovitine treatment
reduced the number of TG3 epitope positive cells from an
average of 17.4±0.79% in sham treated animals to an average
of 6.5±0.78% in roscovitine treated animals (Fig. 8B).
Immunoblotting of brain cortical extracts with monoclonal
antibodies, which recognize the phosphorylated tau, revealed
multiple bands ranging from 31 kDa to 69 kDa. This
observation is consistent with previous research that has
identified tau protein isoforms in rodents [47]. Roscovitine
treatment caused a reduction of tau hyperphosphorylation
epitopes in the ischemic cortical extract (Fig. 8C).
4. Discussion
This study shows that transient cerebral ischemia leads to the
hyperphosphorylation of tau protein and induces PHF-like tau
conformations in wild type female rats. Transgenic mice that
bear mutations of tau have been described for filamentous tau
aggregation [20,43]. However, these mutations in tau protein
are not related to AD, but to a rare neurodegenerative disease,
FTDP17 [48]. Another drawback of mice bearing tau mutations
is that they are not under control of an endogenous tau promoter,
but a much stronger promoter, Thy 1.2 [20,43] that may affect
tau distribution and signal regulation. In the present study, we
demonstrated that transient ischemia causes neuronal loss and
Fig. 8. Inhibition of cyclin dependent kinases reduces tau hyperphosphorylation and tauopathy conformation. (A) Representative immunofluorescent staining of TG3
in sham (upper panel) and roscovitine treated (lower panel) brains after transient cerebral ischemia in the ischemic cortex. Blue indicates nuclear counterstaining with
DAPI, red indicates phospho-tau epitope, TG3 staining, green indicates apoptosis marker TUNEL. Scale bar=100 μm (B) Semi-quantitative analysis on the effects of
roscovitine injection on TG3 immunostaining cell density, in percentage of total cell numbers in frontoparietal cortex. (C) Representative immunoblotting of cortical
extracts with indicated monoclonal antibodies. I: ipsilateral, C: contralateral.
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investigated the potential tau kinases and determined that
aberrant Cdk5 activation is involved in this transient ischemia
induced tau hyperphosphorylation.
These findings are consistent with epidemiological studies
that show that the prevalence of dementia in ischemic stroke
patients is higher than in control subjects [27,28]. This suggests
that NFT formation may be a consequence of a preceding
apoptotic event, which results in the aberrant activation of
protein kinases and further causes tau hyperphosphorylation
and tangle formation. Multiple studies support the conclusion
that the apoptotic signaling pathways are involved in neuronal
loss in AD brains [49–51]. A number of pro-apoptotic factors,
including reactive oxygen species [52,53], β-amyloid [54] andgrowth factor reduction [55,56] may serve as the initiator of
neurodegenerative diseases. Tau hyperphosphorylation and
tangle formation is associated with apoptosis in AD patients
[57–59] and can be induced or enhanced by amyloidal deposits
[42,60].
Our findings that aberrant Cdk5 activation is involved in
transient ischemia induced tauopathy, support the hypothesis
that Cdk5 is involved in AD pathogenesis and NFT formation.
Tau protein kinases II (TPKII), which was purified from bovine
brain microtubules was shown to be identical to the p25–Cdk5
complex [61]. In the human brain, conversion from p35 to p25
is strongly correlated with AD [38,62] and both Cdk5 and p25
are present in neurons that contain NFTs [63]. Cdk5 is
associated with NFTs in vivo and phosphorylates tau on sites
Fig. 9. Proposed model for induction of NFTs by cerebral ischemia/reperfusion
damage.
481Y. Wen et al. / Biochimica et Biophysica Acta 1772 (2007) 473–483found in PHF-tau [64]. Compared with p35, p25 has a
substantially longer half-life and is considered neurotoxic.
The generation of p25 is, therefore, likely to disrupt the normal
regulation of Cdk5, directing Cdk5 to alternate substrates,
causing neurite retraction, microtubule collapse and apoptosis
[38]. P35 cleavage can be induced by calcium influx and
activation of calpain, a calcium-dependent protease [37]. P35–
Cdk5 poorly phosphorylates tau, whereas p25–Cdk5 can
potently induce tau phosphorylation [65]. Cdk5 is also involved
in amyloid induced toxicity [66,67]. In the present study, Cdk5
appears to be involved in tau hyperphosphorylation in vivo.
Cdk5 is strongly activated by the transient cerebral ischemia and
directly associates with tau in an activation-dependent manner
in our study. In contrast, GSK3-β does not appear to be
involved in the initiation of tau-hyperphosphorylation in our
model. During this ischemia–reperfusion process, GSK3-β is
inactivated by the activation of Akt signaling pathways (data
not shown) and is not likely to account for the tau hyperpho-
sphorylation observed in ischemic brains. However, following
the cdk5 induced initial phosphorylation of critical amino acid
residues, GSK3-β may further phosphorylate tau protein and
further negatively regulates its binding to microtubules.
The MCA occlusion model has been widely used for the
evaluation of neurodegenerative mechanisms in stroke and
neuroprotective compounds, such as estrogen [39,68–70]. Our
results indicate that this transient ischemic model may be used
for evaluating tau hyperphosphorylation and NFT-conformation
in vivo, as well as for pharmaceutical screening for NFTs
inhibitors in vivo. Finally, the present data also suggest that
sporadic hypo-perfusion of the brain may initiate and contribute
to the progression of neuropathology in non-familial AD
patients and provides mechanism of the long-observed correla-tion between the ischemic events and the increased prevalence
of AD [28]. As such, prevention of ischemic episodes may serve
as an additional therapeutic approach to prevent the initiation
and progression of AD.
Collectively, our data support the proposed model for NFT-
like tauopathy induced by ischemia/reperfusion shown in Fig. 9.
Ischemia/reperfusion causes a variety of pro-apoptotic pro-
cesses, including energy depletion, excitotoxicity, and oxidative
damage [71,72]. These neurotoxic events lead to disturbances in
cellular Ca2+ homeostasis and results in elevated calpain
activity. Activated calpain cleaves p35 to p25, which confers
potent neurotoxicity in neurons and may lead to sustained
deregulation of Cdk5 in neurons [37,62,73]. The resulting
alteration in kinase activities ultimately leads to the hyperpho-
sphorylation of tau and potentially the formation of neurofi-
brillary tangles [74]. The above process is consistent with the
amyloid hypothesis in AD, which proposes that amyloid beta
peptides disrupt neuronal metabolic and ionic homeostasis and
cause aberrant calcium homeostasis, as well as activation of
kinases and/or inhibition of phosphatases. The resulting
alteration in kinase/phosphatase activities leads to hyperpho-
sphorylation of tau and formation of neurofibrillary tangles
[74]. Our results suggest that cdk5 may be the mediator, which
bridges amyloid toxicity and neurofibrillary tangle formation.
The present study indicates that the transient cerebral
ischemia can induce tau-hyperphosphorylation and potential
NFT formation in a rodent model without genetic alteration.
This could provide valuable information about the pathogenesis
and signal transduction pathways involved in the neurodegen-
erative diseases. Our results also suggest aberrant Cdk5
activation is involved in the tau-hyperphosphorylation in this
animal model and may be a good therapeutic target for the
developments of anti-tangle therapy strategies in AD treat-
ments. Finally, these results suggest that therapies directed at
preventing the early stage of apoptosis may be able to prevent
subsequent neuropathological events seen in AD.
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